Literature DB >> 20196654

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

Kunjal Patel1, David E Shapiro, Susan B Brogly, Elizabeth G Livingston, Alice M Stek, Arlene D Bardeguez, Ruth E Tuomala.   

Abstract

BACKGROUND: Conflicting results have been reported among studies of protease inhibitor (PI) use during pregnancy and preterm birth. Uncontrolled confounding by indication may explain some of the differences among studies.
METHODS: In total, 777 human immunodeficiency virus (HIV)-infected pregnant women in a prospective cohort who were not receiving antiretroviral (ARV) treatment at conception were studied. Births <37 weeks gestation were reviewed, and deliveries due to spontaneous labor and/or rupture of membranes were identified. Risk of preterm birth and low birth weight (<2500 g) were evaluated by using multivariable logistic regression.
RESULTS: Of the study population, 558 (72%) received combination ARV with PI during pregnancy, and a total of 130 preterm births were observed. In adjusted analyses, combination ARV with PI was not significantly associated with spontaneous preterm birth, compared to ARV without PI (odds ratio [OR], 1.22; 95% confidence interval [CI], 0.70-2.12). Sensitivity analyses that included women who received ARV prior to pregnancy also did not identify a significant association (OR, 1.34; 95% CI, 0.84-2.16). Low birth weight results were similar.
CONCLUSIONS: No evidence of an association between use of combination ARV with PI during pregnancy and preterm birth was found. Our study supports current guidelines that promote consideration of combination ARV for all HIV-infected pregnant women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20196654      PMCID: PMC2946359          DOI: 10.1086/651232

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  Management of human immunodeficiency virus infection in pregnancy.

Authors:  D Heather Watts
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

Authors:  Claire Thorne; Simona Fiore; Christoph Rudin
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

3.  Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women.

Authors:  M Ravizza; P Martinelli; A Bucceri; S Fiore; S Alberico; E Tamburrini; C Tibaldi; G Guaraldi; G Anzidei; A Maccabruni; M P Crisalli; M Floridia
Journal:  J Infect Dis       Date:  2007-03-15       Impact factor: 5.226

4.  Combination antiretroviral therapy and duration of pregnancy.

Authors: 
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

5.  Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

Authors:  Joann Schulte; Ken Dominguez; Thomas Sukalac; Beverly Bohannon; Mary Glenn Fowler
Journal:  Pediatrics       Date:  2007-03-12       Impact factor: 7.124

Review 6.  Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis.

Authors:  Athena P Kourtis; Christopher H Schmid; Denise J Jamieson; Joseph Lau
Journal:  AIDS       Date:  2007-03-12       Impact factor: 4.177

7.  Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.

Authors:  I Grosch-Woerner; K Puch; R F Maier; T Niehues; G Notheis; D Patel; S Casteleyn; C Feiterna-Sperling; S Groeger; D Zaknun
Journal:  HIV Med       Date:  2008-01       Impact factor: 3.180

8.  Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study.

Authors:  Fabiola Martin; Graham P Taylor
Journal:  J Infect Dis       Date:  2007-07-09       Impact factor: 5.226

9.  Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

Authors:  Ruth E Tuomala; David E Shapiro; Lynne M Mofenson; Yvonne Bryson; Mary Culnane; Michael D Hughes; M J O'Sullivan; Gwendolyn Scott; Alice M Stek; Diane Wara; Marc Bulterys
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

10.  Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland.

Authors:  Claire L Townsend; Mario Cortina-Borja; Catherine S Peckham; Pat A Tookey
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

View more
  44 in total

1.  In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States.

Authors:  Raymond Griner; Paige L Williams; Jennifer S Read; George R Seage; Marilyn Crain; Ram Yogev; Rohan Hazra; Kenneth Rich
Journal:  AIDS Patient Care STDS       Date:  2011-06-10       Impact factor: 5.078

2.  Antiretrovirals in pregnancy: a note of caution.

Authors:  D Heather Watts; Lynne M Mofenson
Journal:  J Infect Dis       Date:  2012-10-12       Impact factor: 5.226

3.  Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population.

Authors:  Kelesitse Phiri; Paige L Williams; Kate B Dugan; Michael A Fischer; William O Cooper; George R Seage; Sonia Hernandez-Diaz
Journal:  Pediatr Infect Dis J       Date:  2015-07       Impact factor: 2.129

4.  Preterm birth and fetal growth restriction in HIV-infected Brazilian pregnant women.

Authors:  Helena Lucia Barroso Dos Reis; Karina da Silva Araujo; Lilian Paula Ribeiro; Daniel Ribeiro Da Rocha; Drielli Petri Rosato; Mauro Romero Leal Passos; Paulo Roberto Merçon De Vargas
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Mar-Apr       Impact factor: 1.846

5.  Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.

Authors:  Kathleen M Powis; Douglas Kitch; Anthony Ogwu; Michael D Hughes; Shahin Lockman; Jean Leidner; Erik van Widenfelt; Claire Moffat; Sikhulile Moyo; Joseph Makhema; Max Essex; Roger L Shapiro
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

6.  Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.

Authors:  Risa M Hoffman; Erin Leister; Deborah Kacanek; David E Shapiro; Jennifer S Read; Yvonne Bryson; Judith S Currier
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

7.  HIV-exposed infants: rethinking care for a lifelong condition.

Authors:  Nandita Sugandhi; Jessica Rodrigues; Maria Kim; Saeed Ahmed; Anouk Amzel; Mike Tolle; Eric J Dziuban; Scott E Kellerman; Emilia Rivadeneira
Journal:  AIDS       Date:  2013-11       Impact factor: 4.177

8.  Combination antiretroviral use and preterm birth.

Authors:  D Heather Watts; Paige L Williams; Deborah Kacanek; Raymond Griner; Kenneth Rich; Rohan Hazra; Lynne M Mofenson; Hermann A Mendez
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

9.  Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025.

Authors:  Jennifer S Read; Yanling Huo; Kunjal Patel; Marcia Mitchell; Gwendolyn B Scott
Journal:  J Pediatric Infect Dis Soc       Date:  2012-05-03       Impact factor: 3.164

Review 10.  HIV protease inhibitors in pregnancy : pharmacology and clinical use.

Authors:  Nisha Andany; Mona R Loutfy
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.